In 393 patients with early Parkinson disease analysed (410 randomised), 52 weeks of nicotinamide riboside did not help and worsened MDS-UPDRS total score vs placebo (adjusted mean difference 2.72 points; P=.02); non-motor symptom burden also worsened more.
RCTn = 410
Brakedal et al. Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease: The NOPARK Randomized Clinical Trial